Clinical Trial Update: Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BCD-055, a biosimilar infliximab, to Remicade (infliximab) for efficacy and safety in ankylosing spondylitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• BCD-055 (infliximab biosimilar)
• Remicade (infliximab)

Snippet

Sponsor: Biocad | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED